Acorn Capital Advisors, LLC Uro Gen Pharma Ltd. Transaction History
Acorn Capital Advisors, LLC
- $197 Billion
- Q3 2025
A detailed history of Acorn Capital Advisors, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Acorn Capital Advisors, LLC holds 1,259,749 shares of URGN stock, worth $30.6 Million. This represents 12.76% of its overall portfolio holdings.
Number of Shares
1,259,749
Previous 1,259,749
-0.0%
Holding current value
$30.6 Million
Previous $17.3 Billion
45.62%
% of portfolio
12.76%
Previous 11.29%
Shares
2 transactions
Others Institutions Holding URGN
# of Institutions
171Shares Held
43.8MCall Options Held
1.61MPut Options Held
433K-
Rtw Investments, LP New York, NY4.54MShares$111 Million1.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.22MShares$103 Million2.65% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77.6 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.53MShares$61.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.5 Million0.21% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $553M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...